The quality of LDL is a new risk factor in cardiovascular diseases
What is it about?
LDL particles accumulate in the arterial wall, where they become modified and aggregate. We developed a novel assay to measure the susceptibility of plasma LDL particles to aggregate. Importantly, we found that among patients with an established coronary artery disease the presence of aggregation-prone LDL was predictive of future cardiovascular deaths. We further found that differences in the composition of LDL determine their susceptibility for aggregation. The quality of LDL could be improved by a healthy diet or by cholesterol-lowerin medication (PCSK9 inhibition).
Why is it important?
There is a need for new approaches when diagnosing patients with unrecognized risk for cardiovascular disease events. We think that the the measurement of LDL aggregation susceptibility could be used as a novel biomarker of cardiovascular risk that may add predictive power to the conventional risk estimation. The biomarker may facilitate identification of patients who would benefit most from aggressive LDL-lowering therapies.
The following have contributed to this page: Dr Katariina Öörni